Q&A

  • Questions for Deborah Fein: Defining 'optimal outcome'
    3 March 2015
    Comments ( 5 )

    Understanding why some children appear to outgrow their autism diagnosis may provide clues about the biology of the disorder but shouldn’t dictate treatment decisions, says Deborah Fein.

  • Questions for Elizabeth Berry-Kravis: Measuring drug effects
    17 February 2015
    Comments ( 3 )

    Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.

  • Questions for David Mandell: Curbing autism's costs
    20 January 2015
    Comments ( 5 )

    Existing autism therapies do little to lower the lifetime costs of having the disorder, so clinicians should consider more efficient and inexpensive alternatives, says David Mandell.

  • Questions for Eric London: Alternative diagnoses for autism
    2 January 2015
    Comments ( 7 )

    Names such as autism, schizophrenia and intellectual disability are ‘umbrella’ terms that muddy the search for the true cause of an individual’s symptoms, says Eric London. He plans to come up with an alternative diagnostic scheme for developmental disabilities over the next two years.

  • Questions for Thomas Insel: Paths to treatments for autism
    24 November 2014
    Comments ( 0 )

    Finding people who have an autism-linked mutation but no apparent symptoms may be the key to identifying drug targets for the disorder, says Thomas Insel, director of the National Institute of Mental Health.